MedTrace Logo

The INFLUENCE of Cytoreduction on PRO in EOC

NCT03268876 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2024-10-09

No results posted yet for this study

Summary

Based on an improved understanding of how the extent of successful cytoreduction is influenced both by inherent tumor biological characteristics as well as the aggressiveness of the surgical approach this project aims to better define the value of cytoreduction and to use the knowledge gained to develop more individualized therapy and follow-up. This will be achieved through a translational biomedical research approach. Due to the research group's traditions clinical phenotyping, biomarker identification, and clinical trials will be the focus.

Conditions

  • Epithelial Ovarian Cancer

Sponsors & Collaborators

  • Helse Stavanger HF

    collaborator OTHER_GOV

  • Sorlandet Hospital HF

    collaborator OTHER_GOV

  • Haukeland University Hospital

    lead OTHER

Principal Investigators

  • Line Bjørge, MD, PhD, MBA · Helse-Bergen HF

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-03
Primary Completion
2025-12-28
Completion
2030-12-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03268876 on ClinicalTrials.gov